Uniquely formulated to address specific dermal infections, the NanoStat™ technology has demonstrated remarkable clinical efficacy and safety in over 900 patients in two indications, herpes labialis and onychomycosis. In addition, preclinical studies have demonstrated activity against numerous other bacterial, viral and fungal pathogens.